(+/-)-3-[4-(2-methyl-benzoylamino)-5,6,7,8-tetrahydro-naphthalene-1-sulfonylamino]-piperidine-1-carboxylic acid ethyl ester | 723307-17-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: (+/-)-3-[4-(2-methyl-benzoylamino)-5,6,7,8-tetrahydro-naphthalene-1-sulfonylamino]-piperidine-1-carboxylic acid ethyl ester
• 英文别名: Ethyl 3-[[4-[(2-methylbenzoyl)amino]-5,6,7,8-tetrahydronaphthalen-1-yl]sulfonylamino]piperidine-1-carboxylate
• CAS: 723307-17-3
• 化学式: C₂₆H₃₃N₃O₅S
• 分子量: 499.631
• InChiKey: XTTDPUKTJVSIPU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  35
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  113
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Aryl sulfonamides useful as inhibitors of chemokine receptor activity
  申请人：Dai Mingshi

  公开号：US20050085518A1

  公开（公告）日：2005-04-21

  The present invention provides compounds of general formula I: or a pharmaceutically acceptable salt thereof, wherein R 1 , X, Z, R 2 , X., Ar, n, R 3 and R 4 are defined generally and in subsets herein. Compounds of the invention are inhibitors of CCR8 and accordingly are useful for the treatment of a variety of inflammatory and allergic disorders.

  本发明提供一般式I的化合物:或其药学上可接受的盐，其中R1、X、Z、R2、X.、Ar、n、R3和R4在本文中一般和子集中定义。本发明的化合物是CCR8的抑制剂，因此可用于治疗各种炎症和过敏性疾病。
• CCR8 Inhibitors
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20040209948A1

  公开（公告）日：2004-10-21

  Disclosed are CCR8 inhibitors represented by Structural Formulas (I): 1 The variables in Structural Formula (I) are described herein. Also disclosed are methods of treating a subject with a CCR8 mediated condition, especially asthma, by administering one of the disclosed CCR8 inhibitors to the subject.

  本发明涉及由结构式（I）表示的CCR8抑制剂：1结构式（I）中的变量在此文中进行了描述。本发明还涉及通过向受试者给予所披露的CCR8抑制剂之一来治疗CCR8介导的疾病，特别是哮喘的方法。
• CCR8 inhibitors
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20040224978A1

  公开（公告）日：2004-11-11

  Disclosed is an inhibitor of CCR8 that is represented by Structural Formula (I): 1 Also disclosed are pharmaceutical compositions comprising a pharmaceutically acceptable carrier or diluent and a CCR8 inhibitor represented by Structural Formula (I). Also disclosed is a method of treating inflammatory disorders in a subject by administering a CCR8 inhibitor to the subject.

  本发明揭示了一种由结构式(I)所代表的CCR8抑制剂：1。还揭示了包含药学上可接受的载体或稀释剂以及由结构式(I)所代表的CCR8抑制剂的药物组合物。同时还揭示了通过向受试者施用CCR8抑制剂来治疗炎症性疾病的方法。
• US7329755B2
  申请人：——

  公开号：US7329755B2

  公开（公告）日：2008-02-12
• US7378525B2
  申请人：——

  公开号：US7378525B2

  公开（公告）日：2008-05-27